Mirus Announces Transfection Advance: TransIT-X2™ Dynamic Delivery System

New High Performance Broad Spectrum Transfection System, Capable of Delivering DNA and siRNA

Loading media player...

The TransIT-X2(TM) Dynamic Delivery System and Lipofectamine(R) 2000 Transfection Reagent were used to transfect plasmid DNA encoding luciferase into 30 different cell types at three reagent-to-DNA ratios. Luciferase expression was compared at 24 hours post-transfection using a standard luciferase assay. Head-to-head comparisons illustrate superior or equal luciferase expression using TransIT-X2 in 26 of 30 cell types; 11 cell types had expression levels 2-fold higher than Lipofectamine 2000.

MADISON, Wis.--()--Mirus Bio has expanded its transfection expertise with the development of the TransIT-X2™ Dynamic Delivery System, an innovative polymeric system for high efficiency nucleic acid delivery. TransIT-X2 can be used for independent or simultaneous delivery of DNA and siRNA. The TransIT-X2 Dynamic Delivery System offers researchers:

  • Efficiency—Exceptional broad spectrum transfection
  • Versatility—Cutting edge delivery of plasmid DNA and/or siRNA
  • Technology—Novel non-liposomal polymeric delivery

“Profound advances in gene delivery technology have been lacking for some time,” said Scott Hayes, Vice President, Mirus Bio LLC. “As a result, researchers have increasingly resorted to virus-borne or physical disruption technologies to facilitate nucleic acid uptake in difficult-to-transfect cell types despite inherent limitations with each of these methods. A better understanding of the barriers to transfection, and ways to overcome them, has led to the development of a new innovative polymeric dynamic delivery system. This system provides superior delivery of plasmid DNA and siRNA into a vast array of cell types. We feel that this technology provides distinct advantages over other means of transfection and opens new avenues for experimental design.”

In head-to-head testing, TransIT-X2 outperformed the market leader by at least 2-fold in cell types that include: A549, CHO-K1, Hep G2, HCC1143, HUVEC, LNCaP, MDA-MB-468, MDCK, HMEC, Immortalized Keratinocytes and T47D.

For experimental details and testing results, please visit www.TheTransfectionExperts.com.

About Mirus

ONE FOCUS: TRANSFECTION

Every transfection product offered by Mirus Bio is the result of scientific discovery and development from an in-house team of organic chemists, molecular biologists, cell biologists and biochemists. Almost two decades after its founding, transfection continues to be the focal point and passion of Mirus, giving researchers the most reliable products and expertise.

© All rights reserved Mirus Bio LLC. TransIT-X2 is a trademark of Mirus Bio LLC. Lipofectamine is a registered trademark and FreeStyle is a trademark of Life Technologies.

Contacts

Mirus Bio LLC
Laura Juckem, Ph.D., R&D Group Leader
Ph: 608.229.1416
Fax: 608.441.2849
Email: laura.juckem@mirusbio.com

Release Summary

Mirus Announces Transfection Advance: TransIT-X2™ Dynamic Delivery System; New High Performance Broad Spectrum Transfection System, Capable of Delivering DNA and siRNA

Contacts

Mirus Bio LLC
Laura Juckem, Ph.D., R&D Group Leader
Ph: 608.229.1416
Fax: 608.441.2849
Email: laura.juckem@mirusbio.com